Boston Scientific Corporation (BSX) Cash Flow Statement

The ratio being above 1.0 in most quarters suggests that non-cash charges such as amortization of acquired intangibles are inflating the gap between reported profit and cash generation, which is characteristic of an acquisitive device company. The 2026Q1 reading, where operating cash flow of $348.0M was far below net income of $1.3B, is primarily explained by a $915.0M working capital outflow, indicating that the quarter's earnings were not yet converted to cash. Investors should monitor whether working capital absorption recurs, as repeated shortfalls would weaken confidence in the earnings base.

The wide swing in free cash flow margin, combined with a 2025Q1 trough of 7.6%, suggests that quarterly cash generation is driven more by timing effects than by a stable underlying run rate. Capital expenditure has stayed modest at roughly 3-4% of revenue in most quarters, so the volatility appears to originate in operating cash items rather than investment spending. This pattern warrants further investigation before extrapolating any single quarter's margin into forward models.

Dividends were not paid in the reported quarters, while share repurchases appear only in 2026Q2 at $2.0B, which suggests capital is being prioritized toward tuck-in acquisitions consistent with the company's stated growth model. This allocation may improve long-term revenue capacity but ties returns to the successful integration of acquired assets. Investors should monitor whether acquisition spending continues to outpace the cash generated, as this would increase reliance on external financing.